-
公开(公告)号：US5708134A
公开(公告)日：1998-01-13
申请号：US444131
申请日：1995-05-18
IPC分类号： C07K14/00 , C07K1/16 , C07K14/575 , C07K14/65 , C12N1/21 , C12N15/09 , C12N15/17 , C12N15/18 , C12P21/02 , C12P21/04 , C12R1/19
CPC分类号： C07K14/65
摘要： This invention is directed to isolated human AlaGlu-IGF-1, a novel compound which exerts IGF-1 activity and is a valuable precursor in the preparation of IGF-1 itself.
摘要翻译： 本发明涉及分离的人AlaGlu-IGF-1，其是在制备IGF-1本身时发挥IGF-1活性并且是有价值的前体的新型化合物。
-
2.发明授权DNA sequences encoding AlaGlu-IGF-1 and vectors and microorganisms comprising said sequences 失效编码AlaGlu-IGF-1的DNA序列和包含所述序列的载体和微生物
公开(公告)号：US5691168A
公开(公告)日：1997-11-25
申请号：US444142
申请日：1995-05-18
IPC分类号： C07K14/00 , C07K1/16 , C07K14/575 , C07K14/65 , C12N1/21 , C12N15/09 , C12N15/17 , C12N15/18 , C12P21/02 , C12P21/04 , C12R1/19 , C12N5/10 , C12N15/63
CPC分类号： C07K14/65
摘要： This invention is directed to isolated DNA sequences encoding AlaGlu-IGF-1, as well as vectors and microorganisms comprising such sequences.
摘要翻译： 本发明涉及编码AlaGlu-IGF-1的分离的DNA序列，以及包含这些序列的载体和微生物。
-
公开(公告)号：US5849704A
公开(公告)日：1998-12-15
申请号：US458386
申请日：1995-06-02
摘要： A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
摘要翻译： 包含生长激素和组氨酸或组氨酸衍生物作为添加剂或缓冲物质的药物制剂显示出非常高的抗肽脱离，氧化和切割的稳定性。 产品的稳定性允许在室温下以冻干状态或以溶解或再溶解制剂的形式储存和运输。 在组氨酸或其衍生物存在下生长激素的结晶产生比已知方法具有更高纯度的晶体的较高产率。
-
公开(公告)号：US5849700A
公开(公告)日：1998-12-15
申请号：US458385
申请日：1995-06-02
摘要： A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
-
公开(公告)号：US5459052A
公开(公告)日：1995-10-17
申请号：US87477
申请日：1993-07-02
申请人： Lars Skriver , Kim R. Hejn s , Henrik Dalboge
发明人： Lars Skriver , Kim R. Hejn s , Henrik Dalboge
IPC分类号： C07K14/00 , C07K1/16 , C07K14/575 , C07K14/65 , C12N1/21 , C12N15/09 , C12N15/17 , C12N15/18 , C12P21/02 , C12P21/04 , C12R1/19 , A61K38/28
CPC分类号： C07K14/65
摘要： Ala-Glu-IGF-I is a novel compound which exerts IGF-I activity and is a precursor for the preparation of IGF-I. Ala-Glu-IGF-I may by converted to IGF-I by renaturation after recombinant production in E. coli under specified conditions and then cleaving Ala-Glu from the IGF-I.
摘要翻译： Ala-Glu-IGF-I是发挥IGF-I活性的新型化合物，是制备IGF-I的前体。 Ala-Glu-IGF-I可以在大肠杆菌中在特定条件下重组生产后通过复性转化为IGF-I，然后从IGF-I切割Ala-Glu。
-
-
-
-
搜索结果
5 条记录 (耗时 0.018 秒)
